Screening for chronic kidney disease: Where does Europe go?

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 2, 2008, Pages 616-623

  de Jong, Paul E ^a   van der Velde, Marije ^a   Gansevoort, Ron T ^a   Zoccali, Carmine ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC DISEASE; COST; DECISION TREE; ECONOMICS; EUROPE; HUMAN; INCIDENCE; KIDNEY DISEASE; MASS SCREENING; METHODOLOGY; PREVALENCE; REVIEW;

CHRONIC DISEASE; COSTS AND COST ANALYSIS; DECISION TREES; EUROPE; HUMANS; INCIDENCE; KIDNEY DISEASES; MASS SCREENING; PREVALENCE;

EID: 42549122959     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04381007     Document Type: Review

References (42)

1. Bello AK, Nwankwo E, El Nahas AM: Chronic kidney disease: A global challenge. Kidney Int 68[Suppl 98]: S11-S17, 2005
2. Remuzzi G, Weening JJ: Albuminuria as early test for vascular disease. Lancet 365: 556-557, 2005
3. Van Biessen W, de Bacquer D, Verbeke F, Delanghe E, Lameire N, Vanholder R: The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J 28: 478-483, 2007
4. Jungers P, Chauveau P, Descamps-Latscha B, Labrunie M, Giraud E, Man NK, Grünfeld JP, Jacobs C: Age and gender-related incidence of chronic renal failure in a French urban area: A prospective epidemiologic study. Nephrol Dial Transplant 11: 1542-1546, 1996
5. Meisinger C, Döring A, Löwel H, for the KORA study Group: Chronic kidney disease and risk of incident myocardial infarction. and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. Eur Heart J 27: 1245-1250, 2006
6. Magnason RL, Indridason OS, Sigvaldason H, Sigfusson N, Parlsson R: Prevalence and progression of CRF in Iceland: A population-based study. Am J Kidney Dis 40: 955-963, 2002
7. Viktorsdottir O, Palsson R: Andresdottir MB, Aspelund T, Gudnason V, Indridason OS: Prevalence of chronic kidney disease based on estimated glomerular filtration rate and proteinuria. in Icelandic adults. Nephrol Dial Transplant 20: 1799-1807, 2005
8. Cirillo M, Laurenzi M, Mancini M, Zanchetti A, Lombardi C, de Santo NG: Low glomerular filtration rate in the population: Prevalence, associated disorders, and awareness. Kidney Int 70: 800-806, 2006
9. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, van Gilst WH, de Zeeuw D, de Jong PE, for the PREVEND study group: Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 249: 519-526, 2001
10. De Zeeuw D, Hillege HL, de Jong PE: The kidney, a cardiovascular risk marker and a new target for therapy. Kidney Int 68[Suppl 98]: S25-S29, 2005
11. Nierstichting: Professional: Available at: http:// www.professional.nierstichting.nl/preventie/niercheck. Accessed February 8, 2008
12. Kee F, Reaney EA, Maxwell AP, Fogarty DG, Savage G, Patterson CC, on behalf of the TSN renal group: Late referral for assessment of renal failure. J Epidemiol Community Health 59: 386-388, 2005
13. Hallan SI, Dahl K, Oien CM, Grootendorst DC, Aasberg A, Holmen J, Dekker FW: Screening strategies for chronic kidney disease in the general population: Follow-up of cross sectional health survey. BMJ 333: 1047, 2006
14. Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S, Hallan H, Lydersen S, Holmen J: International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 17: 2275-2284, 2006
15. Eriksen BO, Ingrebetsen OC: The progression of chronic kidney disease: A 10-year population-based study on the effects of gender and age. Kidney Int 69: 375-382, 2006
16. Krol E, Rutkowski B, Czekalski S, Sulowicz W, Wiecek A, Lizakowski S, Czarniak P, Szubert B, Karczewska-Maksymienko L, Orlikowska M, Kraszewska E, Magdon RL: Early diagnosis of renal disease: Preliminary results from the pilot study PolNef. Przegl Lek 62: 690-693, 2005
17. Otero A, Gayoso P, Garcia F, de Francisco AL, on behalf of the EPIRCE study group: Epidemiology of chronic renal disease in the Galician population: Results of the pilot Spanish EPIRCE study. Kidney Int 68[Suppl 99]: S16-S19, 2005
18. Drey N, Roderick P, Mullee M, Rogerson M: A population based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis 42: 677-684, 2003
19. John R, Webb M, Young A, Stevens PE: Unreferred chronic kidney disease: A longitudinal study. Am J Kidney Dis 43: 825-835, 2004
20. Gansevoort RT, Verhave JC, Hillege HL, Burgerhof JG, Bakker SJ, de Zeeuw D, de Jong PE, for the PREVEND study group: The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int [Suppl 94]: S28-S35, 2005
21. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third NHANES. Am J Kidney Dis 41: 1-12, 2003
22. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, van Lente F, Levey AS: Prevalence of chronic kidney disease in the Unites States. JAMA 298: 2038-2047, 2007
23. Van Biessen W, Vanholder R, Veys N, Verbeke F, Delanghe J, de Bacquer D, Lameire N: The importance of standardization of creatinine in the implementation of guidelines and recommendations for CKD: Implications for CKD management programmes. Nephrol Dial Transplant 21: 77-83, 2006
24. Lameire N, Jager K, van Biessen W, de Bacquer D, Vanholder R: Chronic kidney disease: A European perspective. Kidney Int 68[Suppl 99]: S30-S38, 2005
25. Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR: Screening for proteinuria in US adults: A cost-effectiveness analysis. JAMA 290: 3101-3114, 2003
26. Stewart JH, McCredie MR, Williams SM, Jager KJ, Trpeski L, McDonald SP: The enigma of hypertensive ESRD: Observations on incidence and trends in 18 European, Canadian, and Asian-Pacific populations. Am J Kidney Dis 48: 183-191, 2006
27. US Department of Health and Human Services: Healthy People 2010: Understanding and Improving Health, Washington, DC, United States Government Printing Office, 2000, pp 4.3-4.25
28. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D: Prevalence of hypertension in the US adult population: Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 25: 305-313, 1995
29. Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157: 2413-2446, 1997
30. Hajjar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 290: 199-206, 2003
31. Nielen MM, Schellevis FG, Verheij RA: Evaluatie campagne "Stop beginnende nierziekte" NIVEL report, Utrecht, Netherlands, NIVEL. Available at: http://www.nivel.nl/pdf/ Evaluatie-campagne-'Stop-beginnende-nierziekte'-2007.pdf. Accessed February 8, 2008
32. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE, for the PREVEND study group: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106: 1777-1782, 2002
33. Verhave JC, Gansevoort RT, Hillege HL, Bakker SJ, de Zeeuw D, de Jong PE, PREVEND Study Group: An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int 66[SuppI 92]: S18-S21, 2004
34. Konta T, Hao Z, Takasaki S, Abiko H, Takahashi T, Ichikawa K, Ikeda A, Ishikawa M, Kawata S, Kato T, Kubota I: Clinical utility of trace proteinuria for microalbuminuria screening in the general population. Clin Exp Nephrol 11: 51-55, 2007
35. Atthobari J, Asselbergs FW, Boersma C, de Vries R, Hillege HL, van Gilst WH, Gansevoort RT, de Jong PE, Atthobari J, de Jong-van den Berg LT, Postma MJ, PREVEND IT Study Group.: Cost-effectiveness of screening for albuminuria and subsequent treatment with an ACE inhibitor to prevent cardiovascular events: A pharmacoeconomic analysis linked to the PREVEND and the PREVEND IT studies. Clin Ther 28: 432-444, 2006
36. Palmer AJ, Annemans L, Palmer AJ, Annemans L, Roze S, Lamotte M, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH: Cost-effectiveness of early irbesartan treatment versus control or late irbesartan treatment in patients with type 2 diabetes, hypertension and renal disease. Diabetes Care 27: 1897-1903, 2004
37. Frimat L, Siewe G, Loos-Ayav C, Briancon S, Kessler M, Aubrege A: Chronic kidney disease: Do generalists and nephrologists differ in their care? Nephrol Ther 2: 127-135, 2006
38. Wyatt C, Konduri V, Eng J, Rohatgi R: Reporting of estimated GFR in the primary care clinic. Am J Kidney Dis 49: 634-641, 2007
39. Boulware LE, Troll MU, Jaar BG, Myers DI, Powe NR: Identification and referral of patients with progressive CKD: A national study. Am J Kidney Dis 48: 192-204, 2006
40. Department of Health: The National Service Framework for Renal Services. Part I and Part II. Available at: http://www.dh.gov.uk/PolicyandGuidance/ healthAndSocialCareTopics/Renal/fs/en
41. The Renal Association: Documents and reports. Available at: http:// www.renal.org/ServiceProvision/servicefiles/IndicatorsGMSContract2006.pdf
42. Klebe B, Irving J, Stevens PE, O'Donoghue DJ, de Lusignan S, Cooley R, Hobbs H, Lamb EJ, John I, Middleton R, New J, Farmer CK: The cost of implementing UK guidelines for the management of chronic kidney disease. Nephrol Dial Transplant 22: 2504-2512, 2007